Avalon GloboCare (ALBT) Competitors $2.27 -0.70 (-23.57%) Closing price 04:00 PM EasternExtended Trading$2.17 -0.10 (-4.19%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ALBT vs. CTXR, ATHA, CASI, PRPH, ALLR, MTEX, EQ, ERNA, PMN, and LPTXShould you be buying Avalon GloboCare stock or one of its competitors? The main competitors of Avalon GloboCare include Citius Pharmaceuticals (CTXR), Athira Pharma (ATHA), CASI Pharmaceuticals (CASI), ProPhase Labs (PRPH), Allarity Therapeutics (ALLR), Mannatech (MTEX), Equillium (EQ), Ernexa Therapeutics (ERNA), Promis Neurosciences (PMN), and Leap Therapeutics (LPTX). These companies are all part of the "pharmaceutical products" industry. Avalon GloboCare vs. Its Competitors Citius Pharmaceuticals Athira Pharma CASI Pharmaceuticals ProPhase Labs Allarity Therapeutics Mannatech Equillium Ernexa Therapeutics Promis Neurosciences Leap Therapeutics Avalon GloboCare (NASDAQ:ALBT) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends and valuation. Does the media favor ALBT or CTXR? In the previous week, Avalon GloboCare had 3 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 4 mentions for Avalon GloboCare and 1 mentions for Citius Pharmaceuticals. Citius Pharmaceuticals' average media sentiment score of 1.89 beat Avalon GloboCare's score of 1.39 indicating that Citius Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Avalon GloboCare Positive Citius Pharmaceuticals Very Positive Do analysts recommend ALBT or CTXR? Citius Pharmaceuticals has a consensus price target of $53.00, suggesting a potential upside of 3,505.44%. Given Citius Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Avalon GloboCare.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalon GloboCare 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Citius Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has preferable earnings & valuation, ALBT or CTXR? Avalon GloboCare has higher revenue and earnings than Citius Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalon GloboCare$1.33M3.23-$7.90M-$19.96-0.11Citius PharmaceuticalsN/AN/A-$39.14MN/AN/A Do institutionals & insiders hold more shares of ALBT or CTXR? 1.4% of Avalon GloboCare shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 37.3% of Avalon GloboCare shares are owned by company insiders. Comparatively, 10.7% of Citius Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is ALBT or CTXR more profitable? Citius Pharmaceuticals has a net margin of 0.00% compared to Avalon GloboCare's net margin of -647.29%. Avalon GloboCare's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Avalon GloboCare-647.29% N/A -50.13% Citius Pharmaceuticals N/A -58.63%-37.67% Which has more volatility & risk, ALBT or CTXR? Avalon GloboCare has a beta of -0.03, meaning that its share price is 103% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. SummaryCitius Pharmaceuticals beats Avalon GloboCare on 8 of the 13 factors compared between the two stocks. Get Avalon GloboCare News Delivered to You Automatically Sign up to receive the latest news and ratings for ALBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALBT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALBT vs. The Competition Export to ExcelMetricAvalon GloboCareMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.63M$3.02B$5.70B$9.56BDividend YieldN/A2.40%4.71%4.06%P/E Ratio-0.1121.0028.1919.94Price / Sales3.23331.94459.6596.38Price / CashN/A42.5736.3258.72Price / Book-0.208.138.295.77Net Income-$7.90M-$55.06M$3.25B$259.21M7 Day Performance-6.20%0.88%0.21%-0.80%1 Month Performance-18.35%15.04%8.71%9.81%1 Year Performance-60.49%2.54%32.76%14.37% Avalon GloboCare Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALBTAvalon GloboCare1.3859 of 5 stars$2.27-23.6%N/A-51.1%$5.63M$1.33M-0.115News CoveragePositive NewsGap DownCTXRCitius Pharmaceuticals3.0698 of 5 stars$1.44-5.9%$53.00+3,580.6%-93.6%$16.27MN/A0.0020Positive NewsATHAAthira Pharma3.7346 of 5 stars$0.43+5.6%$11.25+2,510.2%-87.5%$15.93MN/A-0.2140Positive NewsUpcoming EarningsCASICASI Pharmaceuticals4.2205 of 5 stars$1.22-3.2%$4.00+227.9%-75.5%$15.50M$28.54M-0.48180Positive NewsGap UpPRPHProPhase Labs0.4185 of 5 stars$0.40+10.3%N/A-86.2%$15.18M$6.77M0.00130News CoverageALLRAllarity Therapeutics2.1417 of 5 stars$0.97-2.3%N/A-83.2%$15.03MN/A0.0010Upcoming EarningsAnalyst ForecastMTEXMannatech1.0269 of 5 stars$8.08+2.8%N/A+8.9%$14.94M$115.04M-80.80250EQEquillium2.8791 of 5 stars$0.41-0.2%$3.00+624.5%-45.5%$14.83M$41.10M-1.0640Positive NewsGap DownERNAErnexa Therapeutics1.0767 of 5 stars$1.96-1.0%N/A-93.0%$14.58M$580K-0.2410Positive NewsPMNPromis Neurosciences2.9749 of 5 stars$1.12+154.5%$4.33+286.9%-43.7%$14.39MN/A-22.405News CoveragePositive NewsHigh Trading VolumeLPTXLeap Therapeutics1.9336 of 5 stars$0.34-1.5%$3.38+895.6%-84.6%$14.26MN/A-0.2040Positive NewsGap Up Related Companies and Tools Related Companies Citius Pharmaceuticals Competitors Athira Pharma Competitors CASI Pharmaceuticals Competitors ProPhase Labs Competitors Allarity Therapeutics Competitors Mannatech Competitors Equillium Competitors Ernexa Therapeutics Competitors Promis Neurosciences Competitors Leap Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALBT) was last updated on 7/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalon GloboCare Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalon GloboCare With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALBT Stock Alerts